Waleed Ghanima har stått for idé og gjennomarbeiding og revisjon av manus.
Waleed Ghanima (f. 1964) er spesialist i indremedisin og i blodsykdommer. Han er overlege, forskningssjef og styreleder i Norsk selskap for hematologi.
Forfatter har fylt ut ICMJE-skjemaet og oppgir følgende interessekonflikter: Han har mottatt stipend og/eller honorar fra Bayer, Pfizer, Boehringer Ingelheim, MSD og Novartis.
()
1.
Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342 - 52. [PubMed][CrossRef]
2.
Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799 - 808. [PubMed][CrossRef]
3.
Büller HR, Décousus H, Grosso MA et al. Edoxaban versus Warfarin for the treatment of symptomatic venous thromboembolism N Engl J Med 2013; 369: 1406 - 15. [PubMed][CrossRef]
4.
Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699 - 708. [PubMed][CrossRef]
5.
Schulman S, Kearon C, Kakkar AK et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709 - 18. [PubMed][CrossRef]
6.
Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139 - 51. [PubMed][CrossRef]
7.
Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981 - 92. [PubMed][CrossRef]
8.
Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883 - 91. [PubMed][CrossRef]
9.
Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093 - 104. [PubMed][CrossRef]
10.
Kjerpeseth LJ, Ellekjær H, Selmer R et al. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol 2017; 73: 1417 - 25. [PubMed][CrossRef]
Chai-Adisaksopha C, Crowther M, Isayama T et al. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124: 2450 - 8. [PubMed][CrossRef]
13.
Sherwood MW, Douketis JD, Patel MR et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 2014; 129: 1850 - 9. [PubMed][CrossRef]
14.
Steinberg BA, Peterson ED, Kim S et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015; 131: 488 - 94. [PubMed][CrossRef]
15.
Healey JS, Eikelboom J, Douketis J et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012; 126: 343 - 8. [PubMed][CrossRef]
16.
Dossett LA, Riesel JN, Griffin MR et al. Prevalence and implications of preinjury warfarin use: an analysis of the National Trauma Databank. Arch Surg 2011; 146: 565 - 70. [PubMed][CrossRef]
17.
Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893 - 962. [PubMed][CrossRef]
Halvorsen S, Ghanima W, Fride Tvete I et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother 2017; 3: 28 - 36. [PubMed][CrossRef]
20.
Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093 - 100. [PubMed][CrossRef]
21.
Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713 - 9. [PubMed][CrossRef]
22.
Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893 - 900. [PubMed][CrossRef]
23.
Fang MC, Go AS, Chang Y et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120: 700 - 5. [PubMed][CrossRef]
24.
Johansen H, Rutherford OW, Aamodt AH et al. Nye antikoagulasjonsmidler i kombinasjon med platehemmere. Tidsskr Nor Legeforen 2016; 136: 1543 - 6. [PubMed][CrossRef]
25.
Eikelboom JW, Quinlan DJ, van Ryn J et al. Idarucizumab: The antidote for reversal of Dabigatran. Circulation 2015; 132: 2412 - 22. [PubMed][CrossRef]
26.
Pollack CVJ, Reilly PA, van Ryn J et al. Idarucizumab for Dabigatran reversal - full cohort analysis. N Engl J Med 2017; 377: 431 - 41. [PubMed][CrossRef]
27.
Pollack CVJ, Reilly PA, Eikelboom J et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511 - 20. [PubMed][CrossRef]
28.
Connolly SJ, Milling TJJ, Eikelboom JW et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2016; 375: 1131 - 41. [PubMed][CrossRef]
29.
Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag 2016; 12: 35 - 44. [PubMed]
30.
Niessner A, Tamargo J, Morais J et al. Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2017; 38: 1710 - 6. [PubMed]
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.
Ole-Christian Walter Rutherford og kolleger skriver i en interessant artikkel om antidotbehandling ved bruk av direktevirkende orale antikoagulasjonsmidler (1). De nye DOAK-legemidlene er nyvinninger som erstatter bruken av warfarin i…
Vi takker Dyrkorn og kolleger for deres kommentar til vår artikkel. I nybrottslandet vi befinner oss, med direktevirkende perorale antikoagulasjonsmidler (DOAK) som foretrukne antikoagulanter er belysning av alle relevante aspekter viktig og interessant. Vi er…
Får du ikke vist PDF-filen eller vil lagre filen, kan du høyreklikke på PDF-ikonet. Velg «Lagre mål/fil som..» og hent så opp PDF-filen i for eksempel Acrobat Reader.
Hvorfor omtales ikke serumkonsentrasjonsmålinger av DOAK?
06.03.2018Ole-Christian Walter Rutherford og kolleger skriver i en interessant artikkel om antidotbehandling ved bruk av direktevirkende orale antikoagulasjonsmidler (1). De nye DOAK-legemidlene er nyvinninger som erstatter bruken av warfarin i…